DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $15 | -81.2% | 1,700 | -77.8% | 0.00% | -85.7% |
Q4 2022 | $80 | -99.8% | 7,650 | +23.4% | 0.01% | +133.3% |
Q3 2022 | $47,000 | +135.0% | 6,200 | +811.8% | 0.00% | +200.0% |
Q2 2022 | $20,000 | -52.4% | 680 | -66.0% | 0.00% | -50.0% |
Q1 2022 | $42,000 | -44.0% | 2,000 | -9.1% | 0.00% | -33.3% |
Q4 2021 | $75,000 | +17.2% | 2,200 | -50.7% | 0.00% | 0.0% |
Q3 2021 | $64,000 | +60.0% | 4,460 | +85.8% | 0.00% | +50.0% |
Q2 2021 | $40,000 | +5.3% | 2,400 | +26.3% | 0.00% | 0.0% |
Q1 2021 | $38,000 | -78.9% | 1,900 | -71.2% | 0.00% | -77.8% |
Q4 2020 | $180,000 | +1900.0% | 6,600 | +214.3% | 0.01% | +800.0% |
Q3 2020 | $9,000 | -73.5% | 2,100 | +45.8% | 0.00% | -50.0% |
Q2 2020 | $34,000 | +6.2% | 1,440 | -44.6% | 0.00% | +100.0% |
Q1 2020 | $32,000 | +300.0% | 2,600 | +420.0% | 0.00% | – |
Q4 2019 | $8,000 | +700.0% | 500 | +400.0% | 0.00% | – |
Q3 2019 | $1,000 | -50.0% | 100 | 0.0% | 0.00% | – |
Q2 2019 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q4 2018 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |